作者
Siddharth Patel,Yu Mi Kang,KyungAh Im,Brendon L. Neuen,Stefan D. Anker,Deepak L. Bhatt,Javed Butler,David Z.I. Cherney,Brian Claggett,Robert A. Fletcher,William G. Herrington,Silvio E. Inzucchi,Meg Jardine,Kenneth W. Mahaffey,Darren K. McGuire,John J.V. McMurray,Bruce Neal,Milton Packer,Vlado Perkovic,Scott D. Solomon,Natalie Staplin,Muthiah Vaduganathan,Christoph Wanner,David C. Wheeler,Faı̈ez Zannad,Yujie Zhao,Hiddo J.L. Heerspink,Marc S. Sabatine,Stephen D. Wiviott
摘要
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.